Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
GRACE in partnership with LUNGevity Foundation are thrilled to offer our next webinar on Wednesday, October 24th, at 6:30 PM Eastern/3:30 PM Pacific, with the renowned Dr. David Harpole, Thoracic Surgeon and Professor of Surgery at Duke University Medical Center. Dr. Harpole is a great leader in the field of lung surgery who is also a great collaborator with other specialists in lung cancer who thinks a lot about molecular testing and other advances. He'll join us to speak about advances in lung cancer surgery over the past few years and evolving standards.
The program will include his presentation for about 45 minutes, followed by a question and answer session with our live audience. Registration is free, and through this link.
We'll turn the program into a series of podcasts that will be available here, on the LUNGevity website, and through iTunes and YouTube, but we hope you'll join us and participate in the live program on Wednesday, October 24th.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: